

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2024 (22.08.2024)



(10) International Publication Number
WO 2024/173835 A2

(51) International Patent Classification:
C12N 15/861 (2006.01) A61K 31/711 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:
PCT/US2024/016218

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:
16 February 2024 (16.02.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/485,656 17 February 2023 (17.02.2023) US
63/545,804 26 October 2023 (26.10.2023) US
63/618,348 07 January 2024 (07.01.2024) US
63/549,204 02 February 2024 (02.02.2024) US

Published:
— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
— with sequence listing part of description (Rule 5.2(a))

(71) Applicant: DECIBEL THERAPEUTICS, INC.
[US/US]; 1325 Boylston Street, Suite 500, Boston, MA
02215 (US).

(72) Inventors: HU, Qi-Ying; 1325 Boylston Street, Suite
500, Boston, MA 02215 (US). KEIFER, Orion, Paul,
Jr.; 1325 Boylston Street, Suite 500, Boston, MA 02215
(US). KOEHLER, Seth; 1325 Boylston Street, Suite 500,
Boston, MA 02215 (US). LEE, John; 1325 Boylston Street,
Suite 500, Boston, MA 02215 (US). PALERMO, Adam;
1325 Boylston Street, Suite 500, Boston, MA 02215 (US).
PAN, Ning; 1325 Boylston Street, Suite 500, Boston,
MA 02215 (US). SELLON, Jonathan, B.; 1325 Boylston
Street, Suite 500, Boston, MA 02215 (US). WHITTON,
Jonathon; 1325 Boylston Street, Suite 500, Boston, MA
02215 (US).

(74) Agent: BELLIVEAU, Michael J. et al.; Clark & Elbing
LLP, 101 Federal Street, 15th Floor, Boston, MA 02110
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: METHODS AND COMPOSITIONS FOR ADMINISTERING OTOFERLIN DUAL VECTOR SYSTEMS

(57) Abstract: The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with a mutation in otoferlin (OTOF), by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF protein (e.g., an OTOF isoform 5 protein) and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF protein (e.g., an OTOF isoform 5 protein). These vectors can be used to increase the expression of OTOF in a subject, such as a human subject suffering from sensorineural hearing loss.



WO 2024/173835 A2